Source and scope
This summary is bounded to the recommendations, population and decisions covered by Urticaria. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Canadian urticaria guide 2024
Source-attributed clinical priorities
- First distinguish isolated urticaria or angioedema from anaphylaxis and from bradykinin-mediated angioedema.
- Use a non-sedating antihistamine strategy for uncomplicated histaminergic urticaria and avoid routine corticosteroid dependence.
- Escalate airway, breathing or circulation features immediately and refer recurrent angioedema without hives for specialist assessment.
- Individual wheals usually resolve within 24 hours; fixed painful or bruising lesions suggest another disorder.
sources for this section:Canadian urticaria guide 2024
Practical assessment and management workflow
1
Establish acute versus chronic course, lesion duration, angioedema, triggers, medicines, infections and inducible patterns.
2
Assess airway and circulation before focusing on skin and avoid broad allergy panels without a specific hypothesis.
3
Use a non-sedating antihistamine strategy and remove a plausible trigger where one exists.
4
Review chronic refractory disease for step-up treatment and specialist assessment.
sources for this section:Canadian urticaria guide 2024
Safety, red flags and urgent escalation
- Tongue or laryngeal swelling, wheeze, hypotension or multisystem reaction needs anaphylaxis treatment.
- Angioedema without wheals in a patient taking an ACE inhibitor requires drug review and airway caution.
- Avoid routine long courses of systemic corticosteroid for chronic urticaria.
sources for this section:Canadian urticaria guide 2024
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Canadian urticaria guide 2024
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Canadian urticaria guide 2024
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Allergy, Asthma & Clinical ImmunologyUrticaria2024;20(Suppl 3):64; DOI 10.1186/s13223-024-00931-6 路 accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.